retatrutide phase 2 results weight loss just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a study: • Up to 24.2% mean at 48 weeks 28.7% Weight Loss in New

Endocrine Practice 27(2):8389

BPC 157 10 g/kg, intraperitoneally or per-orally, was given with l-NAME (5 mg/kg intraperitoneally) and/or L-arginine (100 mg/kg intraperitoneally) and it maintained its original beneficial effect

Whats New: ASCO GI 2026 Data on GLP-1 Agents At ASCO GI 2026, several large-scale analyses presented the strongest clinical signals to date linking GLP-1 receptor agonist use with reduced colorectal neoplasia risk

This new, minimally invasive treatment uses 100% natural, plant-based exosomes to harness the bodys natural repair processes and regrow thick, strong, healthy hair in both men and womenwithout surgery and with no downtime

Yanovski, S.Z